Dynamic changes and surveillance function of prion protein expression in gastric cancer drug resistance

Table 1 Demographics of gastric cancer patients at baseline (mean ± SD)

Stage	n	Surgery + chemotherapy	Comprehensivetreatment	KPS beforetreatment	KPS(2 yr later)	ZPS before treatment	ZPS(2 yr later)	CR + PR(%)	Death
I	52	43	9	87.12 ± 12.66	77.31 ± 19.72	1.019 ± 0.772	1.346 ± 1.254	74.6	2
II	66	41	25	77.73 ± 11.12	72.12 ± 16.56	1.803 ± 1.131	2.167 ± 1.344	52.1	1
III	47	32	15	66.81 ± 23.35	41.06 ± 35.20	2.383 ± 1.314	2.830 ± 1.872	36.8	17
IV	20	12	8	57.00 ± 16.46	33.00 ± 31.64	2.650 ± 1.014	3.650 ± 1.459	15.0	9

Male: 134; Female: 51; Mean age: 54.2 ± 21.5. KPS: Karnofsky Performance Scale; ZPS: Zubrod-ECOG-WHO Performance Status; CR: Complete remission; PR: Partial remission.

Table 2 Response to chemotherapy in patients with different prion protein expression

PrPc expression	Case	CR	PR	NC	PD	CR + PR (%)
0	59	7	25	18	9	32 (54.24)
1	30	2	8	13	7	10 (33.33)
2	39	1	9	19	10	10 25.64)
≥ 3	57	0	11	21	25	11 (19.29)

PrPc: Prion protein; CR: Complete remission; PR: Partial remission; NC: Stable disease; PD: Progressive disease.

Table 3 Survival status of patients with different prion protein expression after chemotherapy

PrPc expression	n	6 mo	1 yr	2 yr	Death mortality n (%)
0	59	0	11	45	3(5.10)
1	30	0	8	20	2(6.67)
2	39	3	7	17	7(17.95)
≥ 3	57	5	12	25	17(29.82)

PrPc: Prion protein.

Table 4 Karnofsky performance scale score of patients with different prion protein expression levels

PrPc expression	n	Before treatment	2 yr later	Difference
0	59	85.25 ± 11.40	73.90 ± 22.40	11.35
1	30	81.67 ± 17.34	69.33 ± 25.68	12.34
2	39	74.10 ± 18.77	60.77 ± 31.81	13.33
≥ 3	57	63.90 ± 18.87	45.93 ± 32.00	17.97

PrPC: Prion protein.